Showing results (271-280 of 612) with videos related to

Sort By:
Pageof 62
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 4, 2025
Implementation of a safety program initiative for monitoring infusion disease modifying therapies for multiple sclerosisShuvro Roy, Janel Haughton, Dhanajay Vaidya, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 31, 2024
Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking studyFernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 8, 2024
High-resolution diffusion tensor imaging of the fornix predicts memory function in multiple sclerosisKatherine A Koenig, Ken E Sakaie, Daniel Ontaneda, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 29, 2024
Coronavirus disease 2019 infection among working-aged people with multiple sclerosis and the impact of disease-modifying therapiesChantelle Murley, Emma Pettersson, Jan Hillert, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 19, 2024
Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness ScaleJulia Sabin, Elisa Salas, Jesús Martín-Martínez, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 18, 2023
The six spot step test is superior in detecting walking capacity impairments compared to short- and long-distance walk tests in persons with multiple sclerosisAnders G Skjerbæk, Ulrik Dalgas, Egon Stenager, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendationsDouglas L Arnold, David Li, Marika Hohol, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 10, 2026
Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosisMing-Hui Tai, Brandon Brown, Riley Taiji, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 10, 2026
Early switching to ofatumumab avoids a rebound effect after natalizumab cessation in multiple sclerosis patientsJérôme De Seze, Emmanuel Bernard, Colyne Betsch, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 15, 2026
Continuous ofatumumab treatment until the early third trimester in multiple sclerosis with preserved neonatal immunityKenzo Sakurai, Hideyuki Takeuchi, Tomohiro Katsuta, et al.
Pageof 62